MX368844B - Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina. - Google Patents

Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina.

Info

Publication number
MX368844B
MX368844B MX2015002602A MX2015002602A MX368844B MX 368844 B MX368844 B MX 368844B MX 2015002602 A MX2015002602 A MX 2015002602A MX 2015002602 A MX2015002602 A MX 2015002602A MX 368844 B MX368844 B MX 368844B
Authority
MX
Mexico
Prior art keywords
applications
preparation methods
medicine
imidazoline derivatives
derivatives
Prior art date
Application number
MX2015002602A
Other languages
English (en)
Spanish (es)
Other versions
MX2015002602A (es
Inventor
Sun Piaoyang
Dong Qing
Lu Hejun
Fei Hongbo
Jiang Hongjian
Wang Haowei
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MX2015002602A publication Critical patent/MX2015002602A/es
Publication of MX368844B publication Critical patent/MX368844B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2015002602A 2012-09-04 2013-08-26 Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina. MX368844B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210323870 2012-09-04
PCT/CN2013/082273 WO2014036897A1 (zh) 2012-09-04 2013-08-26 咪唑啉类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2015002602A MX2015002602A (es) 2015-06-10
MX368844B true MX368844B (es) 2019-10-16

Family

ID=50236528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002602A MX368844B (es) 2012-09-04 2013-08-26 Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina.

Country Status (22)

Country Link
US (2) US9586947B2 (OSRAM)
EP (1) EP2894151B1 (OSRAM)
JP (1) JP6262733B2 (OSRAM)
KR (1) KR102189940B1 (OSRAM)
CN (1) CN103958480B (OSRAM)
AU (1) AU2013312587B2 (OSRAM)
BR (1) BR112015004637B1 (OSRAM)
CA (1) CA2883545C (OSRAM)
CY (1) CY1123649T1 (OSRAM)
DK (1) DK2894151T3 (OSRAM)
ES (1) ES2835248T3 (OSRAM)
HR (1) HRP20202050T1 (OSRAM)
HU (1) HUE052904T2 (OSRAM)
LT (1) LT2894151T (OSRAM)
MX (1) MX368844B (OSRAM)
PT (1) PT2894151T (OSRAM)
RS (1) RS61242B1 (OSRAM)
RU (1) RU2639145C2 (OSRAM)
SI (1) SI2894151T1 (OSRAM)
SM (1) SMT202000672T1 (OSRAM)
TW (1) TWI617546B (OSRAM)
WO (1) WO2014036897A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2894151T (pt) * 2012-09-04 2020-12-07 Shanghai hengrui pharmaceutical co ltd Derivados de imidazolina, seus métodos de preparação e suas aplicações em medicina
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2016209349B2 (en) * 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US20170037004A1 (en) * 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
DK3348546T3 (da) 2015-09-10 2020-07-06 Jiangsu Hengrui Medicine Co Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf
CN106518773A (zh) * 2015-09-10 2017-03-22 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的结晶形式及其制备方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
CN107530325B (zh) * 2016-02-19 2021-02-23 江苏恒瑞医药股份有限公司 一种含有咪唑啉类衍生物的药物组合物
WO2018009678A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
CN110167556A (zh) * 2016-07-08 2019-08-23 詹森药业有限公司 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
CA3053805C (en) 2017-02-13 2020-06-30 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
CN112300076B (zh) * 2017-12-13 2022-10-25 江苏恒瑞医药股份有限公司 一种雄性激素受体抑制剂的晶型及其制备方法
CN110684046B (zh) * 2018-07-06 2023-05-12 江苏恒瑞医药股份有限公司 一种新的咪唑啉类衍生物的制备方法
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
FI3853234T3 (fi) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä
WO2020083187A1 (zh) * 2018-10-22 2020-04-30 江苏恒瑞医药股份有限公司 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途
JP7492962B2 (ja) * 2018-12-19 2024-05-30 セルジーン コーポレイション 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療法
MY205718A (en) 2018-12-19 2024-11-07 Celgene Corp Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
CN113929628A (zh) * 2020-06-29 2022-01-14 江苏恒瑞医药股份有限公司 一种咪唑啉衍生物的制备方法
CN113024513A (zh) * 2021-03-22 2021-06-25 中国药科大学 新型雄激素受体降解剂、制备方法和医药用途
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AU2002367147A1 (en) 2001-12-27 2003-07-15 Daiichi Pharmaceutical Co., Ltd. Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
US20060025589A1 (en) * 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
JP4989227B2 (ja) 2004-09-09 2012-08-01 中外製薬株式会社 新規イミダゾリジン誘導体およびその用途
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
KR102481886B1 (ko) * 2005-05-13 2022-12-28 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DK2041123T3 (da) 2006-06-27 2012-05-07 Takeda Pharmaceutical Kondenserede cykliske forbindelser.
MX2011008452A (es) 2009-02-10 2011-12-16 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
EP2416657A4 (en) * 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8450374B2 (en) 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
EP2480544A1 (en) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8916553B2 (en) 2010-07-26 2014-12-23 Bristol-Myers Squibb Company Sulfonamide compounds useful as CYP17 inhibitors
WO2012050868A1 (en) 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
AP3821A (en) 2010-11-03 2016-09-30 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
PT2894151T (pt) * 2012-09-04 2020-12-07 Shanghai hengrui pharmaceutical co ltd Derivados de imidazolina, seus métodos de preparação e suas aplicações em medicina

Also Published As

Publication number Publication date
CA2883545A1 (en) 2014-03-13
BR112015004637A2 (pt) 2017-07-04
JP6262733B2 (ja) 2018-01-17
EP2894151A4 (en) 2016-01-20
AU2013312587A1 (en) 2015-03-19
RU2639145C2 (ru) 2017-12-20
ES2835248T3 (es) 2021-06-22
CY1123649T1 (el) 2022-03-24
CA2883545C (en) 2020-07-07
EP2894151A1 (en) 2015-07-15
RS61242B1 (sr) 2021-01-29
HUE052904T2 (hu) 2021-05-28
JP2015526487A (ja) 2015-09-10
SMT202000672T1 (it) 2021-01-05
SI2894151T1 (sl) 2021-01-29
WO2014036897A1 (zh) 2014-03-13
LT2894151T (lt) 2021-09-10
TW201410655A (zh) 2014-03-16
US20170128422A1 (en) 2017-05-11
US9586947B2 (en) 2017-03-07
US20150225381A1 (en) 2015-08-13
KR102189940B1 (ko) 2020-12-14
AU2013312587B2 (en) 2017-03-16
CN103958480A (zh) 2014-07-30
TWI617546B (zh) 2018-03-11
RU2015110122A (ru) 2016-10-27
EP2894151B1 (en) 2020-11-11
MX2015002602A (es) 2015-06-10
KR20150047591A (ko) 2015-05-04
HRP20202050T1 (hr) 2021-02-19
PT2894151T (pt) 2020-12-07
DK2894151T3 (da) 2021-01-11
BR112015004637B1 (pt) 2022-04-05
HK1198476A1 (zh) 2015-05-08
US9895355B2 (en) 2018-02-20
CN103958480B (zh) 2016-04-06

Similar Documents

Publication Publication Date Title
MX368844B (es) Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina.
NZ745556A (en) Androgen receptor modulator and uses thereof
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
PH12015501385A1 (en) Autotaxin inhibitors
MX2013010898A (es) Novedoso derivados de la pirimidina.
PH12013501600A1 (en) Novel heterocyclic derivatives
EA023222B8 (ru) Пиразолилхиноксалиновые ингибиторы киназы
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA117122C2 (uk) Хінолонові похідні
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MX2015004362A (es) Derivados de ketamina.
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
PH12013502204A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
UA117626C2 (uk) Заміщені 2-тіоксоімідазолідин-4-они та їх спіроаналоги, протираковий активний компонент, фармацевтична композиція, лікарський препарат, спосіб лікування раку простати
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
TN2013000441A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
NZ626715A (en) Novel heteroarylamide derivatives having antiandrogenic properties
TN2013000327A1 (en) Novel heterocyclic derivatives
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази

Legal Events

Date Code Title Description
FG Grant or registration